Table S3.
Reasons why patients with COPD do not have access to the treatment the physician wishes to prescribe, by country: Continuing to Confront COPD International Survey, 2012–2013
| Total (N=1,307) |
USA (N=200) |
Mexico (N=101) |
Brazil (N=101) |
France (N=100) |
Germany (N=100) |
Italy (N=100) |
Spain (N=100) |
UK (N=100) |
NL (N=101) |
Russia (N=100) |
Japan (N=101) |
SK (N=103) |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Among physicians who indicated that 1%–100% of their patients have issues accessing their treatment: ‘Why do your chronic obstructive pulmonary disease patients not have access to their treatment?’* | |||||||||||||
| Preferred treatment too expensive for patient/insurance issues (%) | 70 | 98 | 93 | 94 | 58 | 69 | 12 | 75 | 34 | 11 | 81 | 57 | 49 |
| Preferred treatment not on hospital/clinic formulary (%) | 13 | 2 | 48 | 6 | 4 | 11 | 12 | 11 | 29 | 6 | 35 | 10 | 3 |
| Local guidelines do not recommend preferred treatment (%) | 10 | 1 | 4 | 4 | 4 | 3 | 18 | 13 | 29 | 11 | 1 | 8 | 46 |
| Patient inability to use device or understand how to use preferred treatment (%) | 4 | 3 | 1 | 0 | 2 | 3 | 0 | 7 | 3 | 16 | 0 | 12 | 4 |
| Patient refuses to use the preferred treatment (%) | 3 | 2 | 0 | 1 | 9 | 0 | 24 | 0 | 3 | 11 | 0 | 4 | 3 |
| Poor patient adherence to preferred treatment (%) | 3 | 1 | 1 | 1 | 4 | 0 | 12 | 0 | 0 | 11 | 0 | 2 | 5 |
| Preferred treatment has side effects/risk of contraindication (%) | 2 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 19 | 0 | 2 | 1 |
| Preferred treatment has poor efficacy (%) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 1 | 1 |
| Patient lives alone or has transportation issues (%) | 1 | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Notes:
*
Percentages for each country will sum to greater than 100%; results from an open-ended question asking physicians to provide reasons why they believe their patients with COPD cannot access treatment; no predefined list provided.
Abbreviations: COPD, chronic obstructive pulmonary disease; NL, the Netherlands; SK, South Korea.